The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DSC Fundraising

27 May 2008 07:00

RNS Number : 2014V
Amphion Innovations PLC
27 May 2008
 

Amphion Innovations plc  Partner Company Durham Scientific Crystals, Ltd.  Closes £1.6 million Fundraising

London and New York, 27 May 2008 - Amphion Innovations plc (LSE: AMP) ("Amphion") the developer of medical and technology businesses, today announces that its Partner Company, Durham Scientific Crystals, Ltd. ("DSC") has successfully raised £1.6 million at £8 per share in a Series J financing.DSC, a Durham University spin-out, is pioneering digital colour imaging using x-rays. The Company is applying  ground breaking innovation in materials technology and advanced 3D imaging, radically changing the way x-ray imaging is currently done,  

Amphion now owns approximately 21% of the issued voting share capital on a fully diluted basis.  At £8 per share, DSC is currently valued at £46.5 million following this financing.

The principle use of these funds will be used to enable the continuation of the research and development programme, market research, the commercialisation of products spun-out of research and development, and the initial sales of products in the industrial and security sectors. DSC has signed a contract with the UK Home Office to develop a liquid and small object scanner and airport checkpoint baggage scanners and is progressing similar commercial opportunities in this sector and other areas where the Company's technology can be widely applied.

Richard C.E. Morgan, CEO of Amphion Innovations said, "Despite a more challenging fundraising environment, we have successfully raised an additional £1.6 million at double the valuation of the previous financing. This is a testament to the strength of DSC's innovative technology and we look forward to further positive developments in the future."

Dr. Arnab Basu, Chief Executive Officer of Durham Scientific Crystals said, "The Company is making great progress on both technical and commercial fronts and the support from our investors in this financing round is again a testament to our ability to reach targets and achieve goals."

DSC produces radically improved and more cost effective semiconductor materials than are currently available, which are used in detectors for medical, security, and defense digital x-ray imaging. The Company has commercialised the use of materials based on cadmium telluride, the premier choice for use as digital detectors of x-rays and gamma rays, and will allow for significantly improved imaging in markets such as airport security and medical imaging. In addition to its range of semiconductor materials, detector packages, and non imaging detection systems, DSC also supplies x-ray imaging packages with multi-view capabilities. These x-ray display platforms provide real 3D x-ray imaging for the first time, without specialist viewing equipment.

Cadmium telluride materials are currently too expensive and too difficult to produce to be used in large scale commercial applications. DSC, however, has developed a breakthrough production method to produce these crystals from a vapour phase, rather than the conventional liquid based techniques, enabling the crystals to be produced at an attractive cost and quality enabling their large scale commercial use in the future. The Company is currently developing detectors and its novel imaging system platform based on its fundamental competence of producing high grade cadmium telluride material and its novel 3D XRA™ imaging platforms.

For further information please contact

Amphion Innovations plc  Charlotte Morgan, Communications +1 212 210 6224

Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44 020 7930 0777 (London)

Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley +44 20 7149 6000

Durham Scientific Crystals, Ltd.  Arnab Basu, CEO +44 1740 625 255

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

About Durham Scientific Crystals, Ltd.

Durham Scientific Crystals, Ltd. ("DSC") is a research and development company, which was spun-out from the Physics Department of the University of Durham. The company, based in Sedgefield, County Durham, was formed in April 2003 and has been actively involved in the research and development of semiconductor materials and its unique 3D imaging modality. The company has a world leading capability in manufacturing the cadmium telluride family of semiconductor materials via its patented production process. These materials are used in high performance detectors of x-rays and gamma rays in multiple international markets, including medical imaging, security screening, and industrial inspection. DSC's detectors will enable fast digital imaging, using lower radiation dosage, together with precise materials identification.

In addition to the range of semiconductor materials and non-imaging products, DSC also offers XRA™ imaging packages with True Multi View™ capability and software for material detection. The XRA™ provides real 3D imaging with positional mapping facility for in-line processes at high speed.

On the web: www.dscrystals.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCILFLSEIIVFIT
Date   Source Headline
1st Jul 20155:07 pmRNSHolding(s) in Company
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPreliminary Results
5th Jun 20157:00 amRNSPlacing to raise £1.54 million
19th May 20152:35 pmRNSAppointment of broker
15th Apr 20157:01 amRNSFDA Results
7th Apr 20157:00 amRNSShares Issued for Exercised Warrants
2nd Apr 20157:01 amRNSFirst Day of Dealings of Amphion Partner Company
24th Mar 20153:28 pmRNSIssue of Shares
20th Mar 20157:01 amRNSMotif Bio Ltd Update Re Intention to Float
26th Feb 20157:00 amRNSIssue of Equity
9th Feb 20157:00 amRNSDirector/PDMR Shareholding
2nd Feb 20154:18 pmRNSReissue: Partner Company's Intention to Float
2nd Feb 20158:00 amRNSPartner Company's Intention to Float on AIM
22nd Jan 20151:15 pmRNSDirector/PDMR Shareholding
19th Jan 20157:00 amRNSLandmark Acquisition & Update by Partner Company
6th Jan 20157:00 amRNSDataTern Receives Favourable Appeal Ruling
24th Sep 20147:00 amRNSDirectors' Dealings
19th Sep 20147:00 amRNSHalf Yearly Report
9th Sep 20147:00 amRNSAdditional Draws on Loan Facility
28th Aug 20147:00 amRNSDirectorate Change
7th Aug 20144:51 pmRNSResult of AGM and EGM
10th Jul 20149:10 amRNSDirectors' Dealings
8th Jul 20147:00 amRNSAmphion Partner Motif Can Help Solve Health Crisis
20th Jun 20147:00 amRNSNotice of EGM
18th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSNew Loan Facility
14th Apr 20147:00 amRNSAppeal Ruling
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
28th Jan 20147:00 amRNSConvertible Promissory Note Extension
12th Dec 20137:00 amRNSUpdate on Covertible Promissory Note
13th Nov 20134:33 pmRNSDirector/PDMR Shareholding
13th Nov 20137:00 amRNSPartner Company Update
16th Oct 20137:02 amRNSPartner Company IPO
24th Sep 20137:00 amRNSHalf Yearly Report
12th Sep 20137:02 amRNSPartner company Kromek seeks IPO on AIM
13th Aug 20135:16 pmRNSResult of AGM
1st Jul 201312:02 pmRNSDirector/PDMR Shareholding
28th Jun 20137:00 amRNSFinal Results
18th Apr 20137:00 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSTrading Statement
28th Mar 20137:02 amRNSChange of Adviser
19th Dec 20127:00 amRNSHolding(s) in Company
13th Dec 20127:00 amRNSFundraising
5th Dec 20127:00 amRNSAmphion announces new partnership with Motif
3rd Oct 20127:00 amRNSDirector/PDMR Shareholding
28th Sep 20124:24 pmRNSDirector/PDMR Shareholding
19th Sep 20127:00 amRNSHalf Yearly Report
29th Aug 20127:00 amRNSUpdate - patent litigation
27th Jul 20127:00 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.